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disease pathogenesis, response to treatment, and clinico-
pathological correlates.
Neuroinﬂammation in treated HIV-positive 
individuals: a TSPO PET study
Despite the advent of combined antiretroviral therapy and 
the consequent eﬀective control of HIV RNA in both the 
serum and CSF, many HIV-positive patients still develop 
HIV-associated brain disease, including cognitive impair-
ment. It has been suggested that inﬂammation continues 
in the brain, despite undetectable viral loads, and that this 
inﬂammation is responsible for the gradually accruing cog-
nitive deﬁcits evident in many treated HIV patients.
One of the hypotheses regarding the mechanism of 
chronic immune activation in treated HIV patients relates 
to the concept of microbial translocation: the passage of gut 
ﬂora into the bloodstream due to early CD4 T cell depletion 
in the gastrointestinal tract in the ﬁrst few weeks of HIV 
infection, causing a breach in the mucosal immune sys-
tem. The consequent presence of microbes in the systemic 
circulation (without overt bacteraemia) is postulated to be 
causative in the subsequent chronic inﬂammatory state in 
treated HIV patients.
This cross-sectional, case–control study explored the 
presence of microglial activation in cognitively healthy 
HIV-positive patients on suppressive antiretroviral ther-
apy, correlating this with brain structure and function, 
peripheral chemokines and markers of microbial trans-
location. Twelve treated HIV patients and ten controls 
underwent [11C]PBR28 PET CT scans, volumetric and dif-
fusion MR imaging, cognitive testing, measurement of CSF 
chemokines and HIV RNA, as well as PCR of plasma ribo-
somal 16s rRNA (a marker of microbial translocation).
Introduction
Neuroinﬂammation is associated with increased expression 
of the 18-kDa translocator protein (TSPO), also known as 
the peripheral benzodiazepine receptor (PBR), which is 
present on the mitochondria of activated microglia, astro-
glia and macrophages. TSPO positron emission tomogra-
phy (PET) ligands have been used in neuroinﬂammation 
research for over 20 years. The ﬁrst-generation tracer 11C-
PK11195 has some limitations including low signal-to-
noise ratio making more subtle neuroinﬂammation diﬃcult 
to detect in brain tissue. More recently, second- and third-
generation TSPO-speciﬁc radiotracers have been developed 
to overcome these hurdles and have proven useful in assess-
ment of neuroinﬂammation in a variety of neurological 
and psychiatric conditions. However, one drawback of the 
newer ligands is the need to genotype for rs6971 polymor-
phisms prior to imaging. The polymorphism determines 
radiotracer uptake since low-aﬃnity binders (Thr/Thr) have 
to be excluded, and statistical analyses require adjustments 
depending on whether participants are mixed (Ala/Thr) or 
high aﬃnity (Ala/Ala) binders.
This month’s journal club examines four papers utilising 
TSPO PET imaging in HIV, traumatic brain injury, mul-
tiple sclerosis (MS) and HTLV-1-associated myelopathy 
(HAM), respectively. This imaging modality is used vari-
ously in these four studies to explore questions regarding 
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Microglial activation, as measured by TSPO PET, was 
globally higher in treated HIV patients compared to con-
trols. TSPO uptake was greatest in the subcortical grey 
matter, the basal ganglia in particular. Increased TSPO 
binding correlated with poorer performance in verbal learn-
ing and memory domains on cognitive testing. Increased 
TSPO binding and white matter mean diﬀusivity (MD) on 
diﬀusion imaging also correlated positively. Markers of 
microbial translocation correlated with increased TSPO 
binding, leading the authors to postulate that this phenom-
enon may be a causative factor in brain inﬂammation in 
treated HIV positive patients.
Comment This study lends weight to the hypothesis 
that chronic immune activation continues in HIV patients 
despite apparently eﬀective antiretroviral treatment and that 
the consequent inﬂammation may be responsible for HIV-
associated neurocognitive impairment. Nevertheless, these 
patients were by deﬁnition asymptomatic, so any relatively 
poorer performance on cognitive testing was, therefore, 
subclinical. A longitudinal study might be better placed to 
tackle the issue of causality.
Although this paper contributes to our understanding of 
pathophysiology in treated HIV patients, a study compar-
ing TSPO uptake in asymptomatic HIV patients and those 
with HIV-associated cognitive impairment would be more 
likely to determine whether this imaging modality will 
prove clinically useful in this arena.
Vera J et al (2016) Neurology 86(15):1425–1432.
Imaging of glial cell activation and white matter 
integrity in brains of active and recently retired 
National Football League players
In traumatic brain injury, it is thought that single and 
repeated insults can lead to prolonged immune activation. 
This study aimed to explore whether microglial activation 
is ongoing in the years following sports-related concus-
sive and sub-concussive injuries. Ten young former and 
four active National Football League (NFL) players were 
recruited, in parallel with 16 controls, to undergo [11C]
DPA-713 TSPO imaging alongside structural and diﬀusion 
MRI and neuropsychological testing. Mean time since last 
concussion was 7 years (range 1–21).
TSPO imaging revealed increased microglial activation 
in the NFL players in 8 of 12 regions measured, including 
the supramarginal gyri, mesial temporal lobes and left tem-
poral pole. There was also reduced fractional anisotropy 
on DTI in six of ten regions measured, reﬂective of likely 
altered white matter integrity. There were no volumetric 
diﬀerences on structural MR, nor were there any diﬀer-
ences in neuropsychological parameters.
Comment Although none of the players in this study 
have developed cognitive impairment at this stage in their 
lives, there is some evidence that collision sport profes-
sionals are more likely to develop cognitive, aﬀective and 
behavioural changes later in life. Microglial activation as 
measured with TSPO PET may be one possible mecha-
nism of this; however, a longitudinal study might be better 
placed to answer this question.
The authors hypothesise that microglial activation path-
ways may be therapeutic targets for preventative interven-
tions before the clinical eﬀects of recurrent head injury 
manifest. Given that microglia have reparative functions as 
well as deleterious, this is unlikely to be a straightforward 
undertaking. Another confounding factor when considering 
therapeutic targets is the poor speciﬁcity of TSPO radioli-
gands for microglia since they also bind activated astroglia 
and macrophages.
Coughlin JM et al (2017) JAMA Neurol 74(1):67–74.
Evaluation of the eﬀect of ﬁngolimod treatment 
on microglial activation using serial PET imaging 
in multiple sclerosis
TSPO PET has been used extensively in MS research. 
As might be expected, radiotracer uptake is increased in 
regions that correspond to T2 lesions on MRI. Interest-
ingly, there is also increased tracer uptake in the normal 
appearing white matter (NAWM) and grey matter (GM), 
both in relapsing remitting MS and in progressive disease 
compared with healthy controls.
This study used 11C-(R)-PK11195 PET scans and MRI 
to evaluate the eﬀect of ﬁngolimod on neuroinﬂammation 
in patients with relapsing remitting MS switching from 
another disease-modifying treatment. Ten patients under-
went scans at baseline and 6 months. Seven of these also 
had intermediate scans at 2  months. Eight controls were 
imaged for comparison.
Baseline scans, as expected from previous studies, 
revealed higher TSPO binding in the T2 lesions, NAWM 
and grey matter compared with controls. After 6 months on 
ﬁngolimod, TSPO binding was 12.31% lower (p = 0.040) 
in the T2 lesions compared with baseline, but not in the 
NAWM or GM. Interestingly, TSPO binding in the NAWM 
and GM at 2  months was slightly (but not signiﬁcantly) 
higher in the majority of patients compared to baseline.
Comment MRI has limited utility in monitoring response 
to treatment in MS, so this is one area where TSPO imag-
ing could soon change clinical practice, both in the man-
agement of individual patients and in the development of 
novel disease-modifying treatments, whether for relapsing 
remitting or progressive disease. Despite the unfavourable 
signal-to-noise ratio with 11C-(R)-PK11195, signiﬁcant 
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diﬀerences were still seen in TSPO binding. Unlike novel 
TSPO radioligands, genetic polymorphisms do not aﬀect 
binding aﬃnity of 11C-(R)-PK11195—an important practi-
cal consideration if TSPO imaging is to be useful in clinical 
practice.
Suckersdorﬀ M et  al (2017) J Nucl Med 
ppjnumed.116.183020-32.
Evidence of brain inﬂammation in patients 
with human T-lymphotropic virus type 
1-associated myelopathy (HAM): a multimodal 
imaging study using 11C-PBR28 PET, MR 
T1-weighted and diﬀusion-weighted imaging
More than 10 million people worldwide are infected with 
HTLV-1 of whom 2–4% develop HAM. Clinically, the 
myelopathy manifests predominantly in the thoracic cord; 
however, MRI and histological studies have revealed that 
brain inﬂammation is often present too, albeit subclinically. 
The pathogenesis is thought to be a bystander eﬀect of the 
cellular immune response to HTLV-1-infected lymphocytes 
that enter the central nervous system. At present the only 
available treatments have limited eﬃcacy.
This pilot study examined the brains of ﬁve HAM 
patients and two asymptomatic HTLV-1 carriers. His-
toric healthy control data were also available for analy-
sis. All participants underwent [11C]PBR28 PET, MRI 
(T1-weighted and diﬀusion sequences) and clinical assess-
ment (including cognitive testing and objective gait meas-
ures). There were no consistent abnormalities on neuropsy-
chology. All participants were identiﬁed as high-aﬃnity 
binders on TSPO genotyping.
Global TSPO binding was signiﬁcantly higher in HAM 
patients compared to asymptomatic carriers. Binding was 
also regionally increased in the thalamus. The two HAM 
subjects with severe disease had highest tracer uptake, fol-
lowed by those with moderate and mild disease in decreas-
ing order. Thalamic and brainstem GM volumes were 
reduced in HAM compared to healthy controls and corre-
lated with disease severity, while thalamic mean diﬀusiv-
ity was increased in HAM-severe patients compared with 
controls.
Comment Despite such a small number of study par-
ticipants, the diﬀerences demonstrated here are signiﬁcant. 
The correlation of brain inﬂammation in HAM with meas-
ures of clinical severity suggests that TSPO PET could play 
an important role in future therapeutic research in HTLV. It 
might even prove useful in monitoring individual disease 
activity, though genetic polymorphisms determining aﬃn-
ity binding may prove to be signiﬁcant hurdles. Research 
of TSPO ligand uptake in the cord may also be worth 
pursuing.
Dimber R et al (2016) J Nucl Med 15(12):1905–1912.
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